Juno rebounds after FDA lifts hold

Juno Therapeutics Inc. (NASDAQ:JUNO) gained $2.63 to $30.42 on Wednesday after reporting late Tuesday that FDA lifted a clinical hold on the company's Phase II ROCKET trial of T cell immunotherapy JCAR015 to treat relapsed or refractory acute lymphoblastic leukemia (ALL) (see BioCentury Extra, July 12).

FDA placed the hold last Thursday after the company reported two patient deaths from cerebral edema in the trial. News of the hold had sent Juno's shares down 32% to $27.81 last Friday. ...